Business Description
Akari Therapeutics PLC
NAICS : 541714
SIC : 2834
ISIN : US00972G1085
Share Class Description:
STU:CLA1: ADRTotal Employee Number:
5Description
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.78 | |||||
Equity-to-Asset | 0.42 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 58.9 | |||||
3-Year FCF Growth Rate | 64.3 | |||||
3-Year Book Growth Rate | 9.1 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.27 | |||||
Quick Ratio | 0.27 | |||||
Cash Ratio | 0.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -130 | |||||
Shareholder Yield % | -35.65 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -124.39 | |||||
ROA % | -61.23 | |||||
ROIC % | -25.16 | |||||
3-Year ROIIC % | 33.25 | |||||
ROCE % | -96.74 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | N/A |
N/A
|
N/A
| |||
PE Ratio without NRI | 2.22 | |||||
PEG Ratio | 0.05 | |||||
PB Ratio | 1.13 | |||||
EV-to-EBIT | -0.79 | |||||
EV-to-EBITDA | -0.79 | |||||
EV-to-Forward-Revenue | 0.32 | |||||
EV-to-FCF | -2.09 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.09 | |||||
Earnings Yield (Greenblatt) % | -126.58 | |||||
FCF Yield % | -43.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Akari Therapeutics PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | - | ||
| Beta | 0.6658 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.55 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 134.4 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 134.4 - 134.4 | ||
| Shares Outstanding (Mil) | 1.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Akari Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Akari Therapeutics PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-13 | In 34 days | ||
| General meeting for 2026 | 2026-06-04 14:30 | 134.40 (+0.00%) | ||
| A.G.P.\'s Annual Healthcare Company Showcase | 2026-05-20 17:30 | 134.40 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-19 | 134.40 (+0.00%) | ||
| 0.025:1 Stock Split | 2026-03-31 | 134.40 (+0.00%) | ||
| Annual report for 2025 | 2026-03-30 | 134.40 (+0.00%) | ||
| Webull Financial Webinar | 2026-02-10 13:00 | 134.40 (+0.00%) | ||
| Guidance call for 2026 | 2026-01-13 09:30 | 134.40 (+0.00%) | ||
| Guidance call for 2025 | 2025-11-18 11:00 | 134.40 (+0.00%) | ||
| H.C. Wainwright 27(th) Annual Global Investment Conference | 2025-09-05 07:00 | 134.40 (+0.00%) |
Show
Entries
Akari Therapeutics PLC Frequently Asked Questions
What is Akari Therapeutics PLC(STU:CLA1)'s stock price today?
The current price of STU:CLA1 is €134.40. The 52 week high of STU:CLA1 is €134.40 and 52 week low is €134.40.
When is next earnings date of Akari Therapeutics PLC(STU:CLA1)?
The next earnings date of Akari Therapeutics PLC(STU:CLA1) is 2026-08-13 Est..
Does Akari Therapeutics PLC(STU:CLA1) pay dividends? If so, how much?
Akari Therapeutics PLC(STU:CLA1) does not pay dividend.
Press Release
Articles on Akari Therapeutics PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers